# US 2025/0144057 A1 · Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144057 A1
- Document ID: US20250144057A1
- Status: Published application
- Kind: A1
- Application number: 19/013,881
- Filed: 2025-01-08
- Published: 2025-05-08
- Earliest claimed: 2019-03-01
- Assignees: Flamel Ireland Limited
- Applicants: Flamel Ireland Limited
- Inventors: Julien Grassot; Cendrine Grangeon; Jordan Dubow; Jason Vaughn
- Web page: https://patentgrep.com/patent/US20250144057A1

## CPC

- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/5078: {with drug-free core}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K 9/009: {Sachets, pouches characterised by the material or function of the envelope (with gastric retention A61K9/0065; sachets which are not administered but function merely as a container are classified according to the content, e.g. sachets comprising powder for reconstitution of a drink A61K9/0095)}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.

## Claims

### Claim 1

A method of treating a human patient in need thereof, the method comprising:
forming a mixture comprising a pharmaceutical composition comprising gamma-hydroxybutyrate and a soft food vehicle; and
orally administering the mixture to the human patient after the forming, wherein the orally administering and the forming occur only once nightly.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises an amount of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises immediate-release and modified-release portions, each of which comprises gamma-hydroxybutyrate.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is a dry particulate formulation or a powdered formulation prior to the forming.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mixture has a pH of less than 6.0.

### Claim 6 (depends on 5)

The method of claim 5, wherein the pH of the suspension is maintained for at least 5 minutes after the forming.

### Claim 7 (depends on 6)

The method of claim 6, wherein the pH of the suspension is maintained for up to 30 minutes after the forming.

### Claim 8 (depends on 5)

The method of claim 5, wherein the pH of the mixture is 5.3 to 5.5.

### Claim 9 (depends on 1)

The method of claim 1, wherein the soft food vehicle is selected from the group consisting of pudding, yogurt, and applesauce.

### Claim 10 (depends on 1)

The method of claim 1, wherein the administering occurs within 30 minutes of the forming.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition further comprises hydrogenated vegetable oil, magnesium stearate, methacrylic acid copolymer, and povidone.

### Claim 12 (depends on 7)

The method of claim 7, wherein the pharmaceutical composition further comprises a suspending or viscosifying agent selected from the group consisting of xanthan gum, carrageenan gum, gellan gum, guar gum, sodium alginate, calcium alginate, agar, sodium carboxymethyl cellulose, microcrystalline cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and mixtures thereof.

### Claim 13 (depends on 8)

The method of claim 8, wherein the pharmaceutical composition further comprises an acidifying agent selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, and benzoic acid, or a combination thereof.

### Claim 14 (depends on 1)

The method of claim 1, wherein the soft food vehicle does not have a material impact on a dissolution profile of the pharmaceutical composition.

### Claim 15 (depends on 1)

The method of claim 1, wherein the mixture is bioequivalent to when the pharmaceutical composition is suspended in water.

### Claim 16 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition releases an amount of gamma-hydroxybutyrate into the bloodstream equivalent to from 3.0 g to 12.0 g of sodium oxybate.

### Claim 17

A method of treating a disorder treatable with gamma-hydroxybutyrate in a human in need thereof, the method comprising:
opening a sachet containing a single daily dose of a pharmaceutical composition, wherein the pharmaceutical composition comprises an amount of gamma-hydroxybutyrate equivalent to from 3.0 to 12.0 g of sodium oxybate;
mixing the pharmaceutical composition with a soft food vehicle; and
orally administering the mixture, wherein the opening, mixing, and orally administering occur only once daily.

### Claim 18 (depends on 17)

The method of claim 17, wherein the pharmaceutical composition comprises immediate-release and modified-release portions.

### Claim 19 (depends on 17)

The method of claim 17, wherein the soft food vehicle is selected from the group consisting of pudding, yogurt, and applesauce.

### Claim 20 (depends on 17)

The method of claim 17, wherein the soft food vehicle does not have a material impact on a dissolution profile of the pharmaceutical composition.

### Claim 21 (depends on 17)

The method of claim 17, wherein the mixture is bioequivalent to when the pharmaceutical composition is suspended in water.

### Claim 22 (depends on 17)

The method of claim 17, wherein the pH of the mixture is 5.0 to 6.0.

### Claim 23 (depends on 17)

The method of claim 17, wherein the pH of the mixture is 5.2 to 5.7.

### Claim 24 (depends on 17)

The method of claim 17, wherein the pH of the mixture is 5.3 to 5.5.

### Claim 25

A pharmaceutical mixture comprising:
an immediate release portion comprising gamma-hydroxybutyrate;
a modified release portion comprising gamma-hydroxybutyrate; and
a soft food vehicle,
wherein the ratio of gamma-hydroxybutyrate in the immediate release portion and the modified release portion is from 10/90 to 65/35.

### Claim 26 (depends on 25)

The pharmaceutical mixture of claim 25, further comprising a suspending or viscosifying agent selected from the group consisting of xanthan gum, carrageenan gum, gellan gum, guar gum, sodium alginate, calcium alginate, agar, sodium carboxymethyl cellulose, microcrystalline cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and mixtures thereof.

### Claim 27 (depends on 25)

The pharmaceutical mixture of claim 25, further comprising an acidifying agent selected from the group consisting of malic acid, citric acid, tartaric acid, adipic acid, boric acid, maleic acid, phosphoric acid, ascorbic acid, oleic acid, capric acid, caprylic acid, and benzoic acid.

### Claim 28 (depends on 25)

The pharmaceutical mixture of claim 25, wherein the soft food vehicle is selected from the group consisting of pudding, yogurt, and applesauce.

### Claim 29 (depends on 25)

The pharmaceutical mixture of claim 25, wherein the pH of the mixture is 5.0 to 6.0.

### Claim 30 (depends on 25)

The pharmaceutical mixture of claim 25, wherein the pH of the mixture is 5.2 to 5.7.

### Claim 31 (depends on 25)

The pharmaceutical mixture of claim 25, wherein the pH of the mixture is 5.3 to 5.5.

### Claim 32

A pharmaceutical mixture comprising a soft food vehicle, an immediate release portion, and a modified release portion, wherein the immediate release portion comprises particles comprising gamma-hydroxybutyrate, wherein the modified release portion comprises particles comprising gamma-hydroxybutyrate and a coating, and wherein the coating comprises:
a polymer carrying free carboxylic groups, and
a hydrophobic compound having a melting point equal or greater than 40° C.

### Claim 33

A method of treating a human patient in need thereof, the method comprising:
orally administering a pharmaceutical mixture to a human patient, the pharmaceutical mixture comprising a soft food vehicle and a composition comprising amount of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate, and wherein the composition comprises immediate-release and modified-release portions, each of which comprises gamma-hydroxybutyrate, and wherein the composition comprises a dry particulate or a powder; and
wherein the orally administering occurs only once nightly, and wherein the composition has a pH of ≤6.0.

### Claim 34 (depends on 33)

The method of claim 33, wherein the pH of the composition is 5.0 to 5.9.

### Claim 35 (depends on 33)

The method of claim 33, wherein the pH of the composition is 5.2 to 5.7.

### Claim 36 (depends on 33)

The method of claim 33, wherein the pH of the composition is 5.3 to 5.5.

### Claim 37 (depends on 33)

The method of claim 33, wherein the soft food vehicle does not have a material impact on a dissolution profile of the composition.

### Claim 38 (depends on 33)

The method of claim 33, wherein the mixture is bioequivalent to when the composition is suspended in water.

### Claim 39

A method of treating a human patient in need thereof, the method comprising:
orally administering a pH-adjusted composition to a human patient, the composition comprising a soft food vehicle and an amount of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate, and wherein the composition comprises immediate-release and modified-release portions, each of which comprises gamma-hydroxybutyrate, and wherein the amount of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate comprises a dry particulate or a powder;
wherein the orally administering occurs only once nightly, and wherein the pH of the composition is between 5.0 to 6.0 at administration.

### Claim 40 (depends on 39)

The method of claim 39, wherein the pH of the composition is 5.1 to 5.9 at administration.

### Claim 41 (depends on 39)

The method of claim 39, wherein the pH of the composition is 5.2 to 5.7 at administration.

### Claim 42 (depends on 39)

The method of claim 39, wherein the pH of the composition is 5.3 to 5.5 at administration.

### Claim 43 (depends on 39)

The method of claim 39, wherein the treatment is for narcolepsy, cataplexy, excessive daytime sleepiness, or a sleep related disorder.

### Claim 44 (depends on 39)

The method of claim 39, wherein the soft food vehicle does not have a material impact on a dissolution profile of the composition.

### Claim 45 (depends on 39)

The method of claim 39, wherein the mixture is bioequivalent to when the amount of gamma-hydroxybutyrate equivalent to from 3.0 g to 12.0 g of sodium oxybate is suspended in water.
